Abstract
Amiodarone (AMD), an antiarrhythmic drug, is used cautiously due to its lung toxicity that is characterized by alveolar inflammation followed by fatal fibrosis. AMD induces lung inflammation via increasing the alveolar macrophages and disturbing the balance of T‐helper‐1 (Th1) and Th2 cells cytokines. In this study, the role of the mitogen‐activated protein kinases (MAPKs)/activator protein‐1 (AP‐1) pathway in AMD‐induced lung inflammation was evaluated. Also, the anti‐inflammatory and antifibrotic effects of losartan and/or vitamin D were investigated following 7, 14, and 28 days of AMD administration. AMD resulted in lung injury, inflammatory infiltration, and increased pulmonary levels of inflammatory cytokines starting from Week 1 of exposure. A significant increase in serum levels of interleukin‐4 along with a significant reduction of interferon‐gamma, in addition to strong expression of CD68, were reported after 14 and 28 days of AMD administration reflecting Th1/Th2 cytokines imbalance and the accumulation of alveolar macrophages, respectively. The phosphorylation of MAPKs (ERK1/2, JNK, p38) and AP‐1 was significantly enhanced starting from Week 1 of exposure. Marked expression of transforming growth factor beta‐1 and massive deposition of collagen were detected after 28 days reflecting late fibrosis. All these abnormalities were significantly mitigated by vitamin D and its combination with losartan. Losartan alone has less prominent anti‐inflammatory effects particularly after 28 days; however, it efficiently prevented late fibrosis. This study concludes that MAPKs/AP‐1 pathway is involved in AMD‐induced lung inflammation and that vitamin D and/or losartan could be used as a prophylactic agent to prevent AMD‐induced lung toxicity.